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Implication for health policy/practice/research/medical education:
In an investigation on 52 hemodialysis individuals, we found, non-significant and inverse correlations of serum magnesium with 
serum cholesterol and triglyceride levels.  The association between serum magnesium and dyslipidemia is contradictory, and 
further studies are required to divulge the role of other contributing factors.
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Introduction: Dysregulated lipid profile has been described in patients with chronic renal failure. 
Objectives: In the present study, we investigated the association of serum magnesium level with 
serum triglyceride and cholesterol levels in a group of hemodialysis individuals.
Patients and Methods: This cross-sectional study was carried out on hemodialysis patients 
referred to the Hajar hospital of Shahrekord (2015). Patients who have been on hemodialysis for at 
least three months and had a stable condition for the last two months were recruited. Serum levels 
of magnesium, cholesterol, and triglyceride were measured, and the data was analyzed.
Results: Of 52 patients, 61.5% were males. The mean age of the patients was 60.17 ± 48.70 (range; 
13-78) years and the mean dialysis duration was 44.39 ± 05.52 months. Serum magnesium was 
inversely and insignificantly correlated with serum cholesterol and triglyceride levels. Serum 
magnesium was significantly associated with serum albumin and parathormone. 
Conclusion: We found non-significant and inverse correlations of serum magnesium with serum 
cholesterol and triglyceride levels. The association between serum magnesium and dyslipidemia 
is contradictory, and further studies are required to divulge the role of other contributing factors.
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Introduction
The mortality rate due to cardiovascular diseases is 20 
to 40 times higher in dialysis patients than the general 
population (1,2). Dysregulated lipid profile has been 
described in patients with chronic renal failure (3,4). 
Hypertriglyceridemia occurs in 50–75% of patients with 
chronic renal failure. Although hypercholesterolemia 
is rare in patients with uremia and those undergoing 
dialysis, the decreased level of high-density lipoprotein 
(HDL) cholesterol has been reported in these patients 
(5,6). Magnesium retention is also a common problem 
in patients under hemodialysis. Several epidemiologic 
studies have reported an association between low serum 
magnesium level and the risk of ischemic heart diseases 
such as coronary artery disease and arteriosclerosis, as 
well as mortality in hemodialysis patients (7-9). According 
to the study by Robles et al, magnesium deficiency has 
been associated with perturbed lipid metabolism affecting 
several lipid parameters in both non-uremic and uremic 
patients (6). A relationship has been suggested between 
serum magnesium and risk factors of ischemic heart 
diseases such as lipid parameters, diabetes, and serum 
albumin, phosphorus, and parathormone in hemodialysis 
patients (2). Nevertheless, there is few published data on 
the association of serum magnesium and these parameters 
in hemodialysis patients in Iran. 
Objectives
The aim of this study was to examine the association 
between serum magnesium level and lipid (i.e. serum 
triglyceride and cholesterol levels) and other biochemical 
parameters in Iranian hemodialysis individuals.
Journal of Nephropharmacology, Volume 9, Issue 2, 2020 http://www.jnephropharmacology.com2 
Fooladgar M et al
Patients and Methods 
Study design
This cross-sectional investigation was carried out on 
52 individuals referring to the hemodialysis section of 
Hajar hospital in Shahrekord (2015). Patients who were 
under regular dialysis for at least three months and had 
a stable condition for the last two months were recruited. 
Patients with severe infections, malignancy and history 
of parathyroidectomy were excluded. Blood samples 
were collected from all the patients and transferred to 
the hospital laboratory. Serum levels of magnesium, 
cholesterol and triglyceride were measured using 
photometry method. The duration of dialysis was also 
recorded for all the patients.
Ethical issues
The research followed the tenets of the Declaration of 
Helsinki. Written informed consent was obtained from 
all the patients. This study was approved by the Ethics 
Committee of Shahrekord University of Medical Sciences 
(Ethical code # IR.SKUMS.REC.1394.192).
Statistical analysis
The results were presented as means  ±  SD. Descriptive 
statistics, Pearson’s correlation coefficient, and regression 
analysis were applied to analyze the data. Accordingly, P 
value <0.05 was considered as the statistical significance 
level.
Results
Patients’ characteristics 
Of 52 patients, 61.5% were males. The mean age of the 
patients was 60.17 ± 48.70 (range; 13-78) years and the 
mean duration of dialysis was 44.39 ± 05.52 months 
(Table 1).
Biochemical Parameters
The levels of the biochemical parameters assessed in 
hemodialysis patients have been shown in Table 2.
Association between serum magnesium level and other 
biochemical factors 
As shown in Table 3, the inverse and insignificant 
correlations of serum magnesium with serum cholesterol 
and triglyceride levels were observed. The associations 
between serum magnesium, cholesterol, triglyceride, and 
other biochemical factors have been shown in Table 4.
Discussion
Mortality rates due to cardiovascular diseases are 20 to 40 
times higher in dialysis patients than the general population 
(1,2,10-12). In several studies, dysregulated serum lipid 
parameters including triglyceride and cholesterol, as well 
as serum magnesium levels have been associated with the 
pathogenesis of cardiovascular diseases. In the present 
study, the association of serum magnesium with serum 
lipid and other biochemical parameters was examined.
Of 52 patients investigated in this study, 61.5% were 
males. The mean age of the patients was 60.48 ± 17.70 
(range; 13-78) years. The mean dialysis duration in 
the patients was 44.05 ± 39.52 months. In comparison, 
the mean age of patients in the study of Khatami et al 
was 57.4 ± 15.4 years old with no significant association 
between serum magnesium level and age (2). The mean 
age of patients in the study of Robles et al was 52.76 ± 18.46 
years old and 64% of their patients were males (6). The 
results of these studies were similar to those of the present 
study.
In our study, serum magnesium, triglyceride and 
cholesterol levels were 2.2 ± 0.2 mg/dL, 98.82 ± 65.70 mg/
Table 1. The spectrum of age and hemodialysis duration in the studied 
patients
No. Minimum Maximum Means ± SD
Age (y) 52 13 87 60.17±48.70
Dialysis duration (mon) 52 4 193 44.39±05.52
Table 2. Biochemical parameters measured in hemodialysis patients
No. Mean ± SD
Magnesium (mg/dL) 52 2.2 ± 0.2
Cholesterol (mg/dL) 52 130.42 ± 42.55
Triglyceride (mg/dL) 52 98.82 ± 65.70
Serum calcium (mg/dL) 52 9.1 ± 0.53
Serum albumin (g/dL) 51 4.1 ± 0.36
Bicarbonate (mEq/L) 52 21.1 ± 2.8
Alkaline phosphatase (U/L) 52 266.2 ± 120.5
Serum phosphorus (mg/dL) 51 5.3 ± 1.1
Parathyroid hormone (pg/mL) 52 360.1 ± 238.2
URRa (%) 52 0.61 ± 0.16
Vitamin D (ng/dL) 51 14.4 ± 5.5
Dialysis duration (month) 52 44 ± 39.5
Dialysis doseb 52 517.9 ± 479.4
a Urea reduction ratio; b Sessions of dialysis per week × duration of 
dialysis.
Table 3. The association of serum magnesium with lipid parameters in 
hemodialysis patients
Magnesium 
(mEq/L)
Cholesterol 
(mg/dL)
Triglyceride 
(mg/dL)
Magnesium (mEq/L) 1.00
a
(-)
-0.13
(0.3)
-0.03
(0.8)
Cholesterol  (mg/dL) -0.13(0.3)
1.00
(-)
0.24
(0.08)
Triglyceride (mg/dL) -0.03(0.8)
0.24
(0.08)
1.00
(-)
a The number in the first row for each factor represents the correlation 
coefficient (r) and the number in the second row in parenthesis 
represents P value.
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dL and 130.42 ± 42.55 mg/dL, respectively. Verma et al, on 
the other hand, reported the levels of serum magnesium, 
triglyceride and cholesterol as 2.3 ± 0.98, 174.1 ± 44.62 
mg/dL and 144.54 ± 58.09 mg/dL, respectively (13). In 
the study by Khatami et al, serum magnesium level was 
2.8 ± 0.5 mg/dL (2). Robles et al categorized hemodialysis 
patients in terms of cholesterol levels into <200 mg/dL, 
200-250 mg/dL and >250 mg/dL groups and reported 
the magnesium levels in these groups as 2.0 ± 0.3 mg/dL, 
2.1 ± 0.2 mg/dL and 2.4 ± 0.3 mg/dL mg/dL, respectively. 
Furthermore, serum cholesterol levels were described as 
176.6 ± 19.3 mg/dL, 215.8 ± 11.7 mg/dL and 289.9 ± 49.4 
mg/dL, while serum triglyceride levels were 114.1 ± 48.8 
mg/dL, 177.4 ± 74.6 mg/dL and 225.4 ± 151.2 mg/dL 
in these groups respectively. In accordance with our 
findings, these results showed a positive and insignificant 
correlation between serum triglyceride and cholesterol 
levels in different groups (6). Furthermore, Robles et al 
showed a positive and significant correlation between 
serum magnesium and cholesterol levels; however, an 
inverse and insignificant correlation between these 
parameters was observed in our study. It is possible that 
dietary magnesium restriction led to increased serum 
cholesterol and triglyceride levels suggesting an inverse 
correlation between magnesium and both cholesterol and 
triglyceride levels (14-16). In another study, Baradaran 
et al reported no association between serum lipids and 
neither parathyroid hormone nor serum calcium in 
dialysis patients. Although they described an insignificant 
correlation between serum magnesium and cholesterol 
levels, a positive and significant relationship was reported 
between serum magnesium and triglyceride levels. 
Accordingly, this correlation was attributed to the altered 
metabolism of triglycerides within liver in the presence of 
magnesium (17).
As mentioned, we found inverse and non-significant 
correlations between serum magnesium level and both 
serum cholesterol and triglyceride levels. Furthermore, 
a positive and insignificant correlation was observed 
between cholesterol and triglyceride levels in our study. 
Khatami et al also reported that serum magnesium 
levels positively and significantly correlated with serum 
phosphorus and albumin (2). In the study of Khatami 
et al, patients with low serum magnesium level had also 
significantly lower serum albumin and cholesterol levels 
in comparison with patients who had higher serum 
magnesium levels. On the other hand, serum magnesium 
positively and significantly correlated with serum 
phosphorus level (2). In comparison, serum magnesium 
showed positive and significant correlations with albumin 
and parathormone in the present study.
Nasri et al reported a linear correlation between serum 
magnesium and triglyceride levels in hemodialysis 
patients (18). In comparison, we here observed inverse 
and insignificant correlations between serum magnesium 
with cholesterol and triglyceride levels. In another 
study, serum magnesium levels were lower, and serum 
cholesterol and triglyceride levels were higher in diabetic 
patients than general population indicating an inverse 
correlation between serum magnesium and serum 
cholesterol and triglyceride levels, showing a possible 
role for hypomagnesemia in the pathogenesis of vascular 
complications in diabetic patients (19). In the study of 
Verma et al, the association between serum magnesium 
and total serum cholesterol was insignificant,   however, 
a statistically significant and inverse correlation was 
recorded between serum magnesium and triglyceride 
levels (13). Robles et al also suggested that magnesium 
may participate in the regulation of lipid metabolism in 
hemodialysis patients (6). It has also been reported that 
using magnesium salts as phosphate-binding agents can 
prevent vascular calcification. Furthermore, it has also 
been reported that parathyroid hormone secretion was 
inversely correlated with serum magnesium levels (20). 
Overall, the association between serum magnesium and 
serum cholesterol and triglyceride is contradictory, and 
further studies are required to divulge the role of other 
contributing factors.
Conclusion
We observed inverse and non-significant correlations 
between serum magnesium and both serum cholesterol 
Table 4.  The association of serum magnesium, cholesterol, and triglyceride with other parameters in hemodialysis patients 
Parathyroid 
hormone 
(pg/mL)
Serum 
calcium 
(mg/dL)
Serum 
albumin 
(g/dL)
Bicarbonate 
(mEq/L)
Alkaline 
phosphatase 
(U/L)
Serum 
phosphorus 
(mg/dL)
Vitamin D 
(ng/dL) URR (%)
Dialysis 
duration 
(month)
Dialysis 
dose 
Magnesium 
(mEq/L)
0.28
(0.04)a
0.04
(0.7)
0.50
(<0.001)
0.17
(0.22)
0.01
(0.9)
0.14
(0.31)
-0.23
(0.10)
0.18
(0.20)
0.25
(0.06)
0.27
(0.04)*
Cholesterol 
(mg/dL)
-0.12
(0.3)
-0.16
(0.2)
0.04
(0.7)
0.02
(0.8)
-0.06
(0.6)
-0.07
(0.5)
-0.02
(0.8)
0.004
(0.9)
-0.22
(0.1)
-0.20
(0.1)
Triglyceride 
(mg/dL)
0.11
(0.4)
-0.25
(0.07)
0.005
(0.9)
-0.12
(0.3)
-0.12
(0.3)
-0.05
(0.7)
0.11
(0.4)
-0.03
(0.7)
-0.23
(0.08)
-0.24
(0.08)
a The number in the first row for each factor represents the correlation coefficient (r) and the number in the second row in parenthesis represents P 
value.
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and triglyceride levels. On the other hand, serum 
magnesium significantly correlated with serum albumin 
and parathormone levels. 
Limitations of the study
Our sample size was relatively low, limiting the power of 
our study. Therefore, more multicentric studies on larger 
populations are recommended to validate the repeatability 
of our results.
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